The components of the immune system develop in utero and like a computer, some components are immediately functional (the innate components) but other components must learn the programs and details necessary to function (antigen adaptive components). Like other systems, including military and municipal, the innate and antigen specific components develop into an immune system that helps maintain and surveil the other body processes and systems for aberrations, provide surveillance and protection of the mucoepithelial borders and protection from microbial invasion. Inability, excesses, or errors in these processes cause disease. Aging of the immune system brings immunosenescence, inflammaging, more errors, and decreased surveillance which increases risk for new infections (e.g. COVID-19, influenza), recurrence of latent infections, cancer and autoimmune and inflammatory diseases. With greater understanding of the surveillance, effector and regulatory deficits upon aging, better therapies can be developed.
Citation: Ken S. Rosenthal, Jordan B. Baker. The immune system through the ages[J]. AIMS Allergy and Immunology, 2022, 6(3): 170-187. doi: 10.3934/Allergy.2022013
[1] | Fabrizio Clarelli, Roberto Natalini . A pressure model of immune response to mycobacterium tuberculosis infection in several space dimensions. Mathematical Biosciences and Engineering, 2010, 7(2): 277-300. doi: 10.3934/mbe.2010.7.277 |
[2] | Eduardo Ibarguen-Mondragon, Lourdes Esteva, Leslie Chávez-Galán . A mathematical model for cellular immunology of tuberculosis. Mathematical Biosciences and Engineering, 2011, 8(4): 973-986. doi: 10.3934/mbe.2011.8.973 |
[3] | Suman Ganguli, David Gammack, Denise E. Kirschner . A Metapopulation Model Of Granuloma Formation In The Lung During Infection With Mycobacterium Tuberculosis. Mathematical Biosciences and Engineering, 2005, 2(3): 535-560. doi: 10.3934/mbe.2005.2.535 |
[4] | Chang Gong, Jennifer J. Linderman, Denise Kirschner . A population model capturing dynamics of tuberculosis granulomas predicts host infection outcomes. Mathematical Biosciences and Engineering, 2015, 12(3): 625-642. doi: 10.3934/mbe.2015.12.625 |
[5] | Eduardo Ibargüen-Mondragón, M. Victoria Otero-Espinar, Miller Cerón Gómez . A within-host model on the interaction dynamics between innate immune cells and Mycobacterium tuberculosis. Mathematical Biosciences and Engineering, 2025, 22(3): 511-527. doi: 10.3934/mbe.2025019 |
[6] | Gesham Magombedze, Winston Garira, Eddie Mwenje . Modelling the human immune response mechanisms to mycobacterium tuberculosis infection in the lungs. Mathematical Biosciences and Engineering, 2006, 3(4): 661-682. doi: 10.3934/mbe.2006.3.661 |
[7] | Xu Zhang, Dongdong Chen, Wenmin Yang, JianhongWu . Identifying candidate diagnostic markers for tuberculosis: A critical role of co-expression and pathway analysis. Mathematical Biosciences and Engineering, 2019, 16(2): 541-552. doi: 10.3934/mbe.2019026 |
[8] | Abba B. Gumel, Baojun Song . Existence of multiple-stable equilibria for a multi-drug-resistant model of mycobacterium tuberculosis. Mathematical Biosciences and Engineering, 2008, 5(3): 437-455. doi: 10.3934/mbe.2008.5.437 |
[9] | Ming Zhang, Yingying Zhou, Yanli Zhang . High Expression of TLR2 in the serum of patients with tuberculosis and lung cancer, and can promote the progression of lung cancer. Mathematical Biosciences and Engineering, 2020, 17(3): 1959-1972. doi: 10.3934/mbe.2020104 |
[10] | P. van den Driessche, Lin Wang, Xingfu Zou . Modeling diseases with latency and relapse. Mathematical Biosciences and Engineering, 2007, 4(2): 205-219. doi: 10.3934/mbe.2007.4.205 |
The components of the immune system develop in utero and like a computer, some components are immediately functional (the innate components) but other components must learn the programs and details necessary to function (antigen adaptive components). Like other systems, including military and municipal, the innate and antigen specific components develop into an immune system that helps maintain and surveil the other body processes and systems for aberrations, provide surveillance and protection of the mucoepithelial borders and protection from microbial invasion. Inability, excesses, or errors in these processes cause disease. Aging of the immune system brings immunosenescence, inflammaging, more errors, and decreased surveillance which increases risk for new infections (e.g. COVID-19, influenza), recurrence of latent infections, cancer and autoimmune and inflammatory diseases. With greater understanding of the surveillance, effector and regulatory deficits upon aging, better therapies can be developed.
Tuberculosis (TB) is an infectious disease whose etiological agent is the Mycobacterium tuberculosis (Mtb), in 2015 was one of top 10 causes of death worldwide and it is the second leading cause of death due to communicable diseases, preceded only by the human immunodeficiency virus (HIV). From 2014 to 2015 the rate of decline in TB incidence was
In 2015, there were an estimated 10.4 million new (incident) TB cases worldwide, 1.4 million TB deaths and an additional 0.4 million deaths resulting from TB disease among people living with HIV. Without treatment, the death rate from TB is high. Studies of the natural history of TB disease in the absence of treatment with anti-TB drugs (that were conducted before drug treatments became available) found that about
Most of the infected individuals with Mtb are capable to control the infection and remain in a latent stage in which they cannot transmit the disease. It is estimated that about one third of the world population has latent TB, and around 10
The Mtb bacteria may affect different tissues of the organism, but the most common form of the disease is pulmonary TB. In the lung, Mtb is restricted to discrete sites of infection called granulomas which are well-organized, dynamical structures formed at the site of the bacteria and mediated by specific immune responses during the infection process. The granuloma formation process starts shortly after infection, when the inhaled Mtb is ingested and transported across the alveolar epithelium into the lung tissue and adjacent lymph nodes.
A granuloma is composed of immune cells at various stages of differentiation with the infected macrophages forming the centre of the cellular accumulation. The recruited T cells secrete cytokines that activate infected cells to control their mycobacterial load and activate cytotoxic T cells. The cellular composition of TB granulomatous lesions includes blood-derived infected and uninfected macrophages, foamy macrophages, epithelioid cells (uniquely differentiated macrophages), and multinucleated giant cells (Langerhans cells), B and T lymphocytes, and fibroblasts [10,25,26].
A characteristic of the granulomas is the formation of caseous centre containing necrotic tissue, cell debris and killed mycobacteria. Bacteria are found within macrophages (intracellular bacteria) and within the zone between the necrotic centre and the cellular wall of the granuloma (extracellular bacteria) [7].
The value of an experimental model of mycobacterial persistence has at least two-fold: to uncover fundamental processes associated with clinical latency, and to guide new interventions, diagnostics, antibiotics, and vaccines, to detect, manage, and prevent disease [3,32]. Unfortunately, despite extensive studies on the interactions between Mtb and macrophages, and the granuloma formation, the mechanisms by which pathogen evades anti-microbial responses and establishes persistence within the host cell is not well understood [10].
Numerous theoretical studies have been done to understand the information available on Mtb infection, both from the point of view epidemiological as immune. To this respect, diverse mathematical models have been proposed to assess the impact on the infection progression of factors like Mtb population dynamics, immune system, treatment, and bacterial resistance. See for example [1,2,4,5,6,8,18,35,22,21,24,29,30].
In particular, in this work we propose a model to evaluate the impact of Mtb growth on the outcome of infection. For this end, we formulate a model that takes into account two ways of bacterial growth, the first one results of the average number of bacteria produced in the interior of an infected macrophage, and the other of logistic type that takes into account the competition to infect a macrophage between the outer bacteria. This model is a continuation of previous studies given in [13,14,15,16], and its content is organized in the following way: in the second section we formulate the mathematical model. In the third and fourth sections we do the qualitative analysis of the model. Finally, in the fifth, sixth and seventh sections we present the sensitivity analysis, numerical results and the discussion.
Following [13], we denote by
We assume that non infected macrophages are recruited at a constant rate
dˉMUdt=ΛU−μUˉMU−ˉβˉBˉMU. | (1) |
Infected macrophages grow at a rate
dˉMIdt=ˉβˉBˉMU−ˉαTˉMIˉT−μIˉMI | (2) |
Mtb population grows inside of an infected macrophage up to a limit where the macrophage dies and releases bacteria. Accordingly to this, we assume that growth rate of Mtb inside macrophages is given by
dˉBdt=ˉrμIˉMI+ν(1−ˉBK)ˉB−ˉγUˉMUˉB−μBˉB | (3) |
dˉTdt=ˉkI(1−ˉTTmax)ˉMI−μTˉT. | (4) |
Figure 1 shows the flow diagram of macrophages, T cells and bacteria described in the differential equations (1)-(4). In order to reduce the number of parameters we introduce the following change of variables:
MU=ˉMUΛU/μU,MI=ˉMIΛU/μU,B=ˉBK,T=ˉTTmax. | (5) |
Replacing the new variables the system (1)-(4) becomes
dMUdt=μU−μUMU−βBMUdMIdt=βBMU−αTMIT−μIMI |
dBdt=rMI+ν(1−B)B−γUMUB−μBBdTdt=kI(1−T)MI−μTT, | (6) |
where
αT=ˉαTTmax,β=ˉβK,γU=ˉγUΛUμU,r=ˉrKμIΛUμU,kI=ˉkIΛUμU. | (7) |
It is a simple matter to verify that system (6) satisfies the existence and uniqueness conditions. Moreover, the region of biological interest is given by
Ω={(MUMIBT)∈R4:0≤MU,MI≤1,0≤MU+MI≤1,0≤B≤BM,0≤T≤Tc}, | (8) |
where
The following lemma establishes that system (6) is well posed in the sense that solutions with initial conditions in
Lemma 2.1. The set
The proof is similar to the one given in Lemma 1 of [14].
The equilibria of system (6) are given by the solutions of the following algebraic system
μU−μUMU−βBMU=0βBMU−αTMIT−μIMI=0rMI+ν(1−B)B−γUMUB−μBB=0kI(1−T)MI−μTT=0. | (9) |
It is clear that
MU=μUμU+βBandT=kIMIkIMI+μT. | (10) |
Replacing
MI=βBμU(μU+βB)(αTT+μI), | (11) |
which is equivalent to
MI=(βBμU+βB)(μIαTT+μI)μUμI. |
We observe that
MI=βBμU(kIMI+μT)(μU+βB)[(αT+μI)kIMI+μIμT]. | (12) |
From (12) we obtain the following quadratic equation
M2I+b(B)MI−c(B)=0, | (13) |
where
b(B)=μIμT(αT+μI)kI−βBμU(αT+μI)(μU+βB)c(B)=μTβBμUkI(αT+μI)(μU+βB). | (14) |
Since
MI=ˉg1(B)=−b(B)+√[b(B)]2+4c(B)2. | (15) |
Now, replacing
MI=[βνB2+(μUν−βν+βμB)B+μU(γU+μB)(1−R0)]Br(μU+βB), | (16) |
with
R0=νγU+μB. | (17) |
Equation (16) can be written as
MI=ˉg2(B)=βν[B2+γUν(σ−σc)B+μU(βR0)−1(1−R0)]Br(μU+βB), | (18) |
with
σ=νμUγUβandσc=ν−μBγU. | (19) |
Let us observe that
g1(B)=r(μU+βB)ˉg1(B)g2(B)=[βνB2+(μUν−βν+βμB)B+μU(γU+μB)(1−R0)]B. | (20) |
From (20) we obtain that
Proposition 1. The functions
The roots of the cubic polynomial
B±=−γUν(σ−σc)±√[γUν(σ−σc)]2−4μUR−10(1−R0)β2. | (21) |
Furthermore, we see that the derivatives of
g′1(B)=rβg1(B)+r(μU+βB)2[−b′(B)+b(B)b′(B)+2c′(B)√[b(B)]2+4c(B)]g′2(B)=βν[3B2+2γUν(σ−σc)B+μUβR−10(1−R0)]. | (22) |
From (22) we obtain
g′1(0)=rμUc′(0)b(0)=rμUβμIg′2(0)=νμU(1R0−1). | (23) |
Observe that
g′1(0)−g′2(0)=μU(γU+μB)(R0+R1−1), |
where
R1=rβμI(γU+μB). | (24) |
In order to have a biological interpretation of the existence results for the bacteria-present equilibria in terms of dimensionless variables, in addition to
RB=νμB, Rβ=βμI, RγU=γUμB. | (25) |
In terms of the above parameters,
σ=μUμIRBRβRγU,andσc=RB−1RγU. | (26) |
Furthermore, when
1.
2.
3.
where
ρ=μUμIRBRB−1. |
To analyze the existence of bacteria-present equilibria, we consider two cases,
Proposition 2. If
Proof. Assume first
B±=−γUν(σ−σc)±|γUν(σ−σc)|2. |
Then, for
In the case
Proposition 3. Assume
Proof. The assumptions of the proposition are equivalent to
In the following we will assume
[γUν(σ−σc)]2−4μUR−10(1−R0)β≥0, |
or equivalently,
R∗0=11+β4μU[γUν(σ−σc)]2. |
When
Proposition 4. Assume
1. If
2. If
3. If
Now, if
Proposition 5. Assume
1. If
2. If
3. If
4. If
5. If
In this section we will give a biological interpretation of the parameters
In the formulation of the model is not consider the explicit distinction between internal and external bacteria. However, for the purposes of interpretation we will denote interior (exterior) bacteria the ones in the interior (exterior) of the infected macrophages. In this sense, the product between the average number of bacteria produced by an infected macrophage,
RB=νμB | (27) |
represents the average number of bacteria generated by an exterior Mtb.
On the other hand, in a healthy organism, the population of uninfected macrophages is given by
RγU=γUμB=ˉγUΛUμUμB, | (28) |
represents the average number of invasive bacteria eliminated during their lifetime. Therefore, this number is a measure of the effectiveness of macrophages in controlling bacteria.
Now, once infected, a macrophage on average generates
Rβ=ˉβKμI=βμI, | (29) |
is named the Basic Reproductive Number of the infection since it represents the average number of infected macrophages derived from one infected macrophage when bacteria is introduced for the first time into the organism.
We notice that the parameter
R0=νγU+μB=F(γU)RB, | (30) |
where
F(γU)=μBγU+μB=1−γUγU+μB. | (31) |
Since
Finally, we see that
R1=rβμI(γU+μB)=ˉrˉβKγU+μBΛUμU, |
can be interpreted as the bacteria produced by the fraction of internal bacteria that survive to the control of the population of infected macrophages at equilibrium.
In this section we analyze conditions for stability of the equilibrium points. For this, we calculate the eigenvalues relative to the Jacobian of system (6) evaluated at the equilibrium points, given by
J(MUMIBT)=(−(μU+βB)0−βMU0βB−(αTT+μI)βMU−αTMI−γUBra00(1−T)kI0−(kIMI+μT)), | (32) |
where
a=ν(1−2BK)−γUMU−μB. | (33) |
For the infection free equilibrium
J(P0)=(−μU0−β00−μIβ00rν−(γU+μB)00kI0−μT). | (34) |
Simple calculations show that the eigenvalues are given by
λ2+[μI+γU+μB−ν]]λ+μI(γU+μB)[1−(R0+R1)]=0 |
or equivalently
λ2+[μI+(γU+μB)(1−R0)]]λ+μI(γU+μB)[1−(R0+R1)]=0. | (35) |
From Routh-Hurwitz criterion we conclude that all the eigenvalues of the equation (35) have negative real part if and only if
Proposition 6. The infection free equilibrium
Now, we analyze the stability of bacteria-present equilibria which reflects the infection persistence. From the equations at equilibrium (9) we get the following equalities
μUMU=μU+βBβBMUMI=αTT+μIν(1−2B)−γUMU−μB=−(rMIB+νB)kIMIT=kIMI+μT. | (36) |
Replacing (36) in (34) we obtain
J(Pi)=(−μUMU0−βMU0βB−βBMUMIβMU−αTMI−γUBr−(rMIB+νB)00(1−T)kI0−kIMIT). | (37) |
To get the conditions for negative eigenvalues of
p1(λ)=(λ+μUMU)(λ+βBMUMI)(λ+rMIB+νB)(λ+kIMIT)+rβMU(λ+kIMIT)[βB−(λ+μUMU)]+βMUαTMI(1−T)kI(λ+rMIB+νB)(λ+μUMU)−βMUγUB[(λ+βBMUMI)(λ+kIMIT)+αTMI(1−T)kI]=λ4+s1λ3+s2λ2+s3λ+s4, | (38) |
where
s1=μUMU+βBMUMI+rMIB+νB+kIMITs2=(rMIB+νB)kIMIT+μUMUβBMUMI+(μUMU+βBMUMI)(rMIB+νB+kIMIT)+βMUαTMI(1−T)kI−rβMU−βMUγUBs3=μUMUβBMUMI(rMIB+νB+kIMIT)+(rMIB+νB)kIMIT(μUMU+βBMUMI)+βMUαTMI(1−T)kI(rMIB+νB+μUMU)+rβMUγUB−rβMU(μUMU+kIMIT)−βBγUMU(βBMUMI+kIMIT)s4=μUMUβBMUMI(rMIB+νB)kIMIT+αTMI(1−T)kI(rMIB+νB)μUMU+rβMUβBkIMIT−βMUγUBβBMUMIkIMIT−βMUγUBαTMI(1−T)kI−rβMUμUMUkIMIT. | (39) |
The coefficient
s2=βBMUMI(μUMU+νB+kIMIT)+kIMIT(μUMU+rMIB+νB)+μUMUrMIB+βMUαTMI(1−T)kI+βγUBMU(σ−M2U)s3=(βBMUMI+kIMIT)βγUBMU(σ−M2U)+rβMUβB+rMIB(μUMUkIMIT+βBαTMI(1−T)kI)+[βBMUMIkIMIT+βBαTMI(1−T)kI](μUMU+νB)s4=[βBMUMIkIMIT+αTkIMI(1−T)]βγUBMU(σ−M2U)+αTMI(1−T)kIμUMUrMIB+rβMUβBkIMIT, | (40) |
where
s4>0D1=s1>0D2=s1s2−s3>0D3=(s1s2−s3)s3−s21s4>0. | (41) |
See [9], in order to determine the conditions for which the previous inequalities are satisfied; we define the following constants:
A=μUMU, N=βBMUMI, C=rMIB, D=νB,E=kIMIT,F=βBαTkIMI(1−T),ˉF=αTkIMI(1−T),G=rβMUβBX(MU)=AD−βMUγUB=βγUBMU(σ−M2U). | (42) |
Replacing
s1=A+N+C+D+Es2=N(A+D+E)+E(A+C+D)+AC+F+X(MU)s3=(N+E)X(MU)+G+C(AE+F)+(NE+F)(A+D)s4=(NE+ˉF)X(MU)+ˉFAC+GE | (43) |
Furthermore, after some simplifications,
D2=(N+E)[(A+D)2+C(C+D)+(N+E)(A+C+D)+AC+F]+(A+D)[C(A+E)+X(MU)]+C[AC+X(MU)]D3=r0+r1(EN−ˉF)+r2(ANC−G)+r3(ADEN−ˉFX(MU))+AN2(DEN−CˉF)+(AC+2AN)(D2EN−C2ˉF)+GN(AD−X(MU)), | (44) |
with
r0=172∑n=1anAα1Nα2Cα3Dα4Eα5Fα6ˉFα7Gα8[X(MU)]α9r1=[(A+D)2+AC+2CD](AC+X(MU))+AC(AC+2AE+2CD+2DE+E2+2AN+2DN+EN)r2=s1E2+(AC+AN+DN+X(MU))E+(A+C+D)F+Gr3=(2A+2C+2D+E+N)E+(2A+2C+D+N), |
and
The following theorem summarizes the stability results of the unique bacteria-present equilibrium when
Theorem 4.1. If
Proof. The existence of a unique bacteria-present equilibrium under the hypothesis of the theorem is proved in Proposition 2. It can easily verify that the Routh-Hurwitz conditions for the coefficients given in (43) are satisfied if
Indeed, if
σ=ν−μBγU>γUγU=1, |
which implies
In the following we will assume
Theorem 4.2. Assume
a) if
or
b)
the bacteria-present equilibrium
Proof. As in the above theorem it is enough to show that
D−C=ν−γUMU−μB=γU(σc−MU). |
Since
The stability of
In the following we assume
Theorem 4.3.1 Assume
Ⅰ. If
a. if
b. if
Ⅱ. If
a. if
b. if
Proof. We will prove the stability properties in the cases where there are three equilibria finding intervals in the
MU=f1(B)=μUμU+βB |
is continuous and strictly decreasing function of
˜B=μUβ(1√σ−1), |
is the unique value of
g2(˜B)=βν{[μUβ(1√σ−1)]2+γUν(σ−σc)μUβ(1√σ−1)+μUνβ(γU+μB−ν)}˜B | (45) |
After some simplifications (45) becomes
g2(˜B)=2μUγU√σ(√σ−σ+σc2)˜B. | (46) |
We observe that for
The results of model (6) depend of several parameters, hence it is expected that uncertainities arise in the numerical estimates of those parameters which affect the model results. In this section we are interesting to perform global sensitivity analysis of the parameters related to the bacterial growth, infection rate, and elimination by macrophages (
Parameter | Description | Value | Reference |
growth rate of unfected Mtb | 600 -1000 day |
[19,23,30] | |
infection rate of Mtb | [13,30] | ||
elim. rate of infected Mtb by T cell | [13,30] | ||
nat. death rate of |
0028-0.0033 day |
[22,30] | |
nat. death rate of |
0.011 day |
[22,35,30] | |
growth rate of Mtb | 0.36 -0.52 day |
[12,20,38] | |
natural death rate of Mtb | 0.31 -0.52 day |
[39,30] | |
elim. rate of Mtb by |
[30] | ||
carrying cap. of Mtb in the gran. | [7] | ||
growth rate of T cells | [11] | ||
maximum recruitment of T cells | 5.000 day |
[11] | |
natural death rate of T cells | 0.33 day |
[35,30] | |
Average Mtb released by one |
0.05-0.2 day |
[30,35] |
We sampled the space of the input values using LHS with a uniform probability distribution. In LHS, each parameter probability distribution is divided into
Figure 3 shows the standard regression coefficients (SCR) for
Next, we quantify the impact of the variations or sensitivity of the parameters
In this section we present numerical simulations of system (6). It is important to make clear that the parameters variability depends of the immunological conditions of each patient. However, we will present some estimations based in a bibliographic revision.
In the following we verify numerically the existence of three equilibria for conditions according to the results given in last sections. Taking the parameters
Therefore, the equilibrium solutions are
P1=(0.82980.18470.00810.2028),P2=(0.45750.360.07650.3315),P3=(0.10990.48750.55660.4018). | (47) |
Numerical simulations confirm that
P(0)=(0.457461,0.360034,B(0),0.331513), |
with
P1=(0.00190.00040.26790.4802),P2=(0.00090.00040.43150.1). | (48) |
Theorem 4.3 implies that
In this work we explore the effect on the progression to TB disease due to the population growth of tuberculosis bacterium and the patient immune system control. For this end we formulated a non linear system of ordinary differential equations to describe in a simple way the interaction of Mtb with T cells and macrophages. The immune response to TB infection is a very complex phenomena that involve process of cellular differentiation and activation that have been described in several works [30,35], but due to the difficulties that involve modelling all of these process, we only considered the most important cells in the activation of the immune system against Mtb.
The model formulated in this work arises as a necessity to complement previous works given in [13,14,15]. Here we assume two forms of bacterial growth, the first one is the growth in the interior of the infected macrophages considered in previous works, and the second one is a logistic growth of external bacteria competing for the resources. Both assumptions are justified [17,26]
As it was expected, the complexity of the results increased with the assumption of logistic growth. The qualitative analysis of the model revealed different scenarios in which there is always the infection-free state, while depending on certain conditions there may be one, two or even three bacteria-present equilibria. An interesting fact is that for certain values of the parameters there are two kinds of bi-stability regions. In the first one the disease-free equilibrium and the bacteria-present equilibrium coexist, which means that depending on the initial conditions of the host and bacteria, the infection will be cleared out or will progress to TB, either in a latent or active form. In the second case the introduction of bacteria always will progress to infection, and depending on the initial conditions, the population will approach to a state with low or with high number of Mtb. The first state could be associated to latent TB, and the second one to active TB.
The above results were obtained in terms of the following parameters: ⅰ) number of bacteria generated by an external bacteria,
The qualitative analysis and numerical results suggest that for
When
On the other hand, sensitive analysis of the model parameters indicates why macrophagues are not enough to control an initial invasion by Mtb and the need of the immune system to carry out a more complex defensive mechanisms to contain infection by Mtb such as the recruitment of different elements of the immune system, and the formation of granulomas.
Concluding, in this work we proved that including competition between bacteria it is possible to obtain a greater variety of scenarios observed in the development of pulmonary tuberculosis.
We want to thank anonymous referees for their valuable comments that helped us to improve the paper. E. Ibarguen-Mondragón and E. M. Burbano-Rosero acknowledge support from project approved by ACUERDO No 182-01/11/2016 (VIPRI-UDENAR). Lourdes Esteva acknowledges support from project IN-112713, PAPIIT-UNAM.
[1] | Simon AK, Hollander GA, McMichael A (2015) Evolution of the immune system in humans from infancy to old age. P Roy Soc B-Biol Sci 282: 20143085. https://doi.org/10.1098/rspb.2014.3085 |
[2] |
Nikolich-Žugich J (2018) The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol 19: 10-19. https://doi.org/10.1038/s41590-017-0006-x ![]() |
[3] |
Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009) The aging of the immune system. Transplant Int 22: 1041-1050. https://doi.org/10.1111/j.1432-2277.2009.00927.x ![]() |
[4] |
Weyand CM, Goronzy JJ (2016) Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc 13: S422-S428. https://doi.org/10.1513/AnnalsATS.201602-095AW ![]() |
[5] |
Vasto S, Caruso C (2004) Immunity & ageing: a new journal looking at ageing from an immunological point of view. Immun Ageing 1: 1-4. https://doi.org/10.1186/1742-4933-1-1 ![]() |
[6] |
Shaw AC, Joshi S, Greenwood H, et al. (2010) Aging of the innate immune system. Curr Opin Immunol 22: 507-513. https://doi.org/10.1016/j.coi.2010.05.003 ![]() |
[7] | Hossain Z, Reza AHMM, Qasem WA, et al. (2022) Development of the immune system in the human embryo. Pediatr Res 2022: 1-5. https://doi.org/10.1038/s41390-022-01940-0 |
[8] |
Márquez EJ, Chung CH, Marches R, et al. (2020) Sexual-dimorphism in human immune system aging. Nat Commun 11: 751. https://doi.org/10.1038/s41467-020-14396-9 ![]() |
[9] |
Rosenthal KS (2018) Immune monitoring of the body's borders. AIMS Allergy Immunol 2: 148-164. https://doi.org/10.3934/Allergy.2018.3.148 ![]() |
[10] |
Rosenthal KS (2017) Dealing with garbage is the immune system's main job. MOJ Immunol 5: 00174. https://doi.org/10.15406/moji.2017.05.00174 ![]() |
[11] |
Melville JM, Moss TJM (2013) The immune consequences of preterm birth. Front Neurosci 7: 79. https://doi.org/10.3389/fnins.2013.00079 ![]() |
[12] |
Herzenberg LA, Tung JW (2006) B cell lineages: documented at last!. Nat Immunol 7: 225-226. https://doi.org/10.1038/ni0306-225 ![]() |
[13] |
Hornef MW, Torow N (2020) ‘Layered immunity’ and the ‘neonatal window of opportunity’—timed succession of non-redundant phases to establish mucosal host–microbial homeostasis after birth. Immunology 159: 15-25. https://doi.org/10.1111/imm.13149 ![]() |
[14] |
Filias A, Theodorou GL, Mouzopoulou S, et al. (2011) Phagocytic ability of neutrophils and monocytes in neonates. BMC Pediatr 11: 29. https://doi.org/10.1186/1471-2431-11-29 ![]() |
[15] |
Hebel K, Weinert S, Kuropka B, et al. (2014) CD4+ T cells from human neonates and infants are poised spontaneously to run a nonclassical IL-4 program. J Immunol 192: 5160-5170. https://doi.org/10.4049/jimmunol.1302539 ![]() |
[16] |
Leeansyah E, Loh L, Nixon DF, et al. (2014) Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. Nat Commun 5: 3143. https://doi.org/10.1038/ncomms4143 ![]() |
[17] |
Silva-Santos B, Schamel WW, Fisch P, et al. (2012) γδ T-cell conference 2012: close encounters for the fifth time. Eur J Immunol 42: 3101-3105. https://doi.org/10.1002/eji.201270101 ![]() |
[18] |
Gibbons D, Fleming P, Virasami A, et al. (2014) Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants. Nat Med 20: 1206-1210. https://doi.org/10.1038/nm.3670 ![]() |
[19] |
Gibbons DL, Haque SF, Silberzahn T, et al. (2009) Neonates harbor highly active γδ T cells with selective impairments in preterm infants. Eur J Immunol 39: 1794-1806. https://doi.org/10.1002/eji.200939222 ![]() |
[20] |
Pou C, Nkulikiyimfura D, Henckel E, et al. (2019) The repertoire of maternal anti-viral antibodies in human newborns. Nat Med 25: 591-596. https://doi.org/10.1038/s41591-019-0392-8 ![]() |
[21] |
Sarvas H, Seppälä I, Kurikka S, et al. (1993) Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 13: 145-151. https://doi.org/10.1007/BF00919271 ![]() |
[22] |
Fouda GG, Martinez DR, Swamy GK, et al. (2018) The Impact of IgG transplacental transfer on early life immunity. Immunohorizons 2: 14-25. https://doi.org/10.4049/immunohorizons.1700057 ![]() |
[23] |
Katherine Z, Sanidad KZ, Amir M, et al. (2022) Maternal gut microbiome-induced IgG regulates neonatal gut microbiome and immunity. Sci Immunol 7: eabh3816. https://doi.org/10.1126/sciimmunol.abh3816 ![]() |
[24] |
Kalliomäki M, Ouwehand A, Arvilommi H, et al. (1999) Transforming growth factor-β in breast milk: a potential regulator of atopic disease at an early age. J Allergy Clin Immunol 104: 1251-1257. https://doi.org/10.1016/S0091-6749(99)70021-7 ![]() |
[25] |
Brodin P (2022) Immune-microbe interactions early in life: A determinant of health and disease long term. Science 376: 945-950. https://doi.org/10.1126/science.abk2189 ![]() |
[26] |
Olin A, Henckel E, Chen Y, et al. (2018) Stereotypic immune system development in newborn children. Cell 174: 1277-1292. https://doi.org/10.1016/j.cell.2018.06.045 ![]() |
[27] |
Johnson JL, Jones MB, Cobb BA (2015) Polysaccharide A from the capsule of Bacteroides fragilis induces clonal CD4+ T cell expansion. J Biol Chem 290: 5007-5014. https://doi.org/10.1074/jbc.M114.621771 ![]() |
[28] |
Kelchtermans H, Billiau A, Matthys P (2008) How interferon-γ keeps autoimmune diseases in check. Trends Immunol 29: 479-486. https://doi.org/10.1016/j.it.2008.07.002 ![]() |
[29] |
Stiemsma LT, Reynolds LA, Turvey SE, et al. (2015) The hygiene hypothesis: current perspectives and future therapies. Immunotargets Ther 4: 143-157. https://doi.org/10.2147/ITT.S61528 ![]() |
[30] |
Okada H, Kuhn C, Feillet H, et al. (2010) The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol 160: 1-9. https://doi.org/10.1111/j.1365-2249.2010.04139.x ![]() |
[31] |
Hill DA, Spergel JM (2018) The atopic march: Critical evidence and clinical relevance. Ann Allerg Asthma Im 120: 131-137. https://doi.org/10.1016/j.anai.2017.10.037 ![]() |
[32] |
Neu N, Duchon J, Zachariah P (2015) TORCH Infections. Clin Perinatol 42: 77-103. https://doi.org/10.1016/j.clp.2014.11.001 ![]() |
[33] |
Menzies D (2000) What does tuberculin reactivity after bacille Calmette–Guérin vaccination tell us?. Clin Infect Dis 31: S71-S74. https://doi.org/10.1086/314075 ![]() |
[34] |
Sherwood ER, Burelbach KR, McBride MA, et al. (2022) Innate immune memory and the host response to infection. J Immunol 208: 785-792. https://doi.org/10.4049/jimmunol.2101058 ![]() |
[35] |
Loske J, Röhmel J, Lukassen S, et al. (2022) Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 40: 319-324. https://doi.org/10.1038/s41587-021-01037-9 ![]() |
[36] |
Azzi T, Lünemann A, Murer A, et al. (2014) Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124: 2533-2543. https://doi.org/10.1182/blood-2014-01-553024 ![]() |
[37] |
Takahashi T, Iwasaki A (2021) Sex differences in immune responses. Science 371: 347-348. https://doi.org/10.1126/science.abe7199 ![]() |
[38] |
Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16: 626-638. https://doi.org/10.1038/nri.2016.90 ![]() |
[39] |
Klein SL, Jedlicka A, Pekosz A (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 10: 338-349. https://doi.org/10.1016/S1473-3099(10)70049-9 ![]() |
[40] |
Pinheiro I, Dejager L, Libert C (2011) X-chromosome-located microRNAs in immunity: Might they explain male/female differences?. Bioessays 33: 791-802. https://doi.org/10.1002/bies.201100047 ![]() |
[41] |
Griesbeck M, Ziegler S, Laffont S, et al. (2015) Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women. J Immunol 195: 5327-5336. https://doi.org/10.4049/jimmunol.1501684 ![]() |
[42] |
Haitao T, Vermunt JV, Abeykoon J, et al. (2020) COVID-19 and sex differences: mechanisms and biomarkers. Mayo Clin Proc 95: 2189-2203. https://doi.org/10.1016/j.mayocp.2020.07.024 ![]() |
[43] |
Asano T, Boisson B, Onodi F, et al. (2021) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 6: eabl4348. https://doi.org/10.1126/sciimmunol.abl4348 ![]() |
[44] |
Aomatsu M, Kato T, Kasahara E, et al. (2013) Gender difference in tumor necrosis factor-α production in human neutrophils stimulated by lipopolysaccharide and interferon-γ. Biochem Bioph Res Co 441: 220-225. https://doi.org/10.1016/j.bbrc.2013.10.042 ![]() |
[45] |
Brunsing RL, Owens KS, Prossnitz ER (2013) The G protein-coupled estrogen receptor (GPER) agonist G-1 expands the regulatory T-cell population under TH17-polarizing conditions. J Immunother 36: 190-196. https://doi.org/10.1097/CJI.0b013e31828d8e3b ![]() |
[46] |
Jaillon S, Berthenet K, Garlanda C (2019) Sexual dimorphism in innate immunity. Clin Rev Allerg Immu 56: 308-321. https://doi.org/10.1007/s12016-017-8648-x ![]() |
[47] |
Arruvito L, Sanz M, Banham AH, et al. (2007) Expansion of CD4+CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol 178: 2572-2578. https://doi.org/10.4049/jimmunol.178.4.2572 ![]() |
[48] |
Mor G, Aldo P, Alvero A (2017) The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol 17: 469-482. https://doi.org/10.1038/nri.2017.64 ![]() |
[49] |
Krop J, Heidt S, Claas FHJ, et al. (2020) Regulatory T cells in pregnancy: it is not all about FoxP3. Front Immunol 11: 1182. https://doi.org/10.3389/fimmu.2020.01182 ![]() |
[50] |
Hanna J, Goldman-Wohl D, Hamani Y, et al. (2006) Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 12: 1065-1074. https://doi.org/10.1038/nm1452 ![]() |
[51] |
Le Bouteiller P (2013) Human decidual NK cells: unique and tightly regulated effector functions in healthy and pathogen-infected pregnancies. Front Immunol 4: 404. https://doi.org/10.3389/fimmu.2013.00404 ![]() |
[52] |
Sojka DK, Yang L, Yokoyama WM (2019) Uterine natural killer cells. Front Immunol 10: 960. https://doi.org/10.3389/fimmu.2019.00960 ![]() |
[53] |
Yang SL, Wang HY, Li DJ, et al. (2019) Role of decidual natural killer cells at the maternal–fetal interface during pregnancy. Reprod Dev Med 3: 165-169. https://doi.org/10.4103/2096-2924.268161 ![]() |
[54] |
Piccinni MP, Lombardelli L, Logiodice F, et al. (2016) How pregnancy can affect autoimmune diseases progression?. Clin Mol Allergy 14: 11. https://doi.org/10.1186/s12948-016-0048-x ![]() |
[55] |
Bupp MRG, Jorgensen TN (2018) Androgen-induced immunosuppression. Front Immunol 9: 794. https://doi.org/10.3389/fimmu.2018.00794 ![]() |
[56] |
Trigunaite A, Dimo J, Jørgensen TN (2015) Suppressive effects of androgens on the immune system. Cellular Immunol 294: 87-94. https://doi.org/10.1016/j.cellimm.2015.02.004 ![]() |
[57] |
Angele MK, Pratschke S, Hubbard WJ, et al. (2014) Gender differences in sepsis. Virulence 5: 12-19. https://doi.org/10.4161/viru.26982 ![]() |
[58] |
Meier A, Chang J, Chan E, et al. (2009) Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 15: 955-959. https://doi.org/10.1038/nm.2004 ![]() |
[59] |
Meester I, Manilla-Muñoz E, León-Cachón, RBR, et al. (2020) SeXY chromosomes and the immune system: reflections after a comparative study. Biol Sex Differ 11: 1-13. https://doi.org/10.1186/s13293-019-0278-y ![]() |
[60] |
Russi AE, Walker-Caulfield ME, Ebel ME, et al. (2015) Cutting edge: c-Kit signaling differentially regulates type 2 innate lymphoid cell accumulation and susceptibility to central nervous system demyelination in male and female SJL mice. J Immunol 194: 5609-5613. https://doi.org/10.4049/jimmunol.1500068 ![]() |
[61] |
Zhang MA, Rego D, Moshkova M, et al. (2012) Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way. P Natl Acad Sci USA 109: 9505-9510. https://doi.org/10.1073/pnas.1118458109 ![]() |
[62] |
Tadount F, Doyon-Plourde P, Rafferty E, et al. (2020) Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females?—A systematic review. Vaccine 38: 444-459. https://doi.org/10.1016/j.vaccine.2019.10.091 ![]() |
[63] |
Gee J, Marquez P, Su J, et al. (2021) First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020-January 13. MMWR Morb Mortal Wkly Rep 70: 283-288. https://doi.org/10.15585/mmwr.mm7008e3 ![]() |
[64] |
López-Otín C, Blasco MA, Partridge L, et al. (2013) The hallmarks of aging. Cell 153: 1194-1217. https://doi.org/10.1016/j.cell.2013.05.039 ![]() |
[65] |
Cuervo AM, Macian F (2014) Autophagy and the immune function in aging. Curr Opin Immunol 29: 97-104. https://doi.org/10.1016/j.coi.2014.05.006 ![]() |
[66] |
Gustafson CE, Kim C, Weyand CM, et al. (2020) Influence of immune aging on vaccine responses. J Allergy Clin Immunol 145: 1309-1321. https://doi.org/10.1016/j.jaci.2020.03.017 ![]() |
[67] |
Ciabattini A, Nardini C, Santoro F, et al. (2018) Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol 40: 83-94. https://doi.org/10.1016/j.smim.2018.10.010 ![]() |
[68] | Fülöp T, Foris G, Worum I, et al. (1985) Age-dependent alterations of Fcγ receptor-mediated effector functions of human polymorphonuclear leucocytes. Clin Exp Immunol 61: 425-432. |
[69] |
Butcher S, Chahel H, Lord JM (2000) Ageing and the neutrophil: No appetite for killing?. Immunology 100: 411-416. https://doi.org/10.1046/j.1365-2567.2000.00079.x ![]() |
[70] |
Solana R, Tarazona R, Gayoso I, et al. (2012) Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 24: 331-341. https://doi.org/10.1016/j.smim.2012.04.008 ![]() |
[71] |
Mylotte JM, Naughton B, Saludades C, et al. (1998) Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia. J Am Geriatr Soc 46: 1538-1544. https://doi.org/10.1111/j.1532-5415.1998.tb01539.x ![]() |
[72] |
Hasegawa T, Feng Z, Yan Z, et al. (2020) Reduction in human epidermal Langerhans cells with age is associated with decline in CXCL14-mediated recruitment of CD14+ monocytes. J Invest Dermatol 140: 1327-1334. https://doi.org/10.1016/j.jid.2019.11.017 ![]() |
[73] |
Zegarska B, Pietkun K, Giemza-Kucharska P, et al. (2017) Changes of Langerhans cells during skin ageing. Postepy Dermatol Alergol 34: 260-267. https://doi.org/10.5114/ada.2017.67849 ![]() |
[74] |
Salimi S, Hamlyn JM (2020) COVID-19 and crosstalk with the hallmarks of aging. J Gerontol A-Biol 75: e34-e41. https://doi.org/10.1093/gerona/glaa149 ![]() |
[75] |
Becklund B, Purton J, Ramsey C, et al. (2016) The aged lymphoid tissue environment fails to support naïve T cell homeostasis. Sci Rep 6: 30842. https://doi.org/10.1038/srep30842 ![]() |
[76] |
Thompson HL, Smithey MJ, Surh CD, et al. (2017) Functional and homeostatic impact of age-related changes in lymph node stroma. Front Immunol 8: 706. https://doi.org/10.3389/fimmu.2017.00706 ![]() |
[77] |
Naylor K, Li G, Vallejo AN, et al. (2005) The influence of age on T cell generation and TCR diversity. J Immunol 174: 7446-7452. https://doi.org/10.4049/jimmunol.174.11.7446 ![]() |
[78] |
Goronzy JJ, Lee WW, Weyand CM (2007) Aging and T-cell diversity. Exp Gerontol 42: 400-406. https://doi.org/10.1016/j.exger.2006.11.016 ![]() |
[79] |
Moro-García MA, Alonso-Arias R, López-Vázquez A, et al. (2012) Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age 34: 479-495. https://doi.org/10.1007/s11357-011-9240-6 ![]() |
[80] |
Pangrazzi L, Weinberger BZ (2020) T cells, aging and senescence. Exp Gerontol 134: 110887. https://doi.org/10.1016/j.exger.2020.110887 ![]() |
[81] |
Solana R, Tarazona R, Aiello AE, et al. (2012) CMV and Immunosenescence: from basics to clinics. Immun Ageing 9: 23. https://doi.org/10.1186/1742-4933-9-23 ![]() |
[82] |
Frasca D, Blomberg BB, Fuldner R, et al. (2018) “Aging and immunity” symposium: Meeting report. Exp Gerontol 105: 1-3. https://doi.org/10.1016/j.exger.2017.12.004 ![]() |
[83] |
Goronzy J, Weyand C (2013) Understanding immunosenescence to improve responses to vaccines. Nat Immunol 14: 428-436. https://doi.org/10.1038/ni.2588 ![]() |
[84] |
Feehan J, Tripodi N, Apostolopoulos V (2021) The twilight of the immune system: The impact of immunosenescence in aging. Maturitas 147: 7-13. https://doi.org/10.1016/j.maturitas.2021.02.006 ![]() |
[85] |
Raynor J, Lages CS, Shehata H, et al. (2012) Homeostasis and function of regulatory T cells in aging. Curr Opin Immunol 24: 482-487. https://doi.org/10.1016/j.coi.2012.04.005 ![]() |
[86] |
Neiman M, Hellström C, Just D, et al. (2019) Individual and stable autoantibody repertoires in healthy individuals. Autoimmunity 52: 1-11. https://doi.org/10.1080/08916934.2019.1581774 ![]() |
[87] |
Khan MWA, Al Otaibi A, Sherwani S, et al. (2020) Glycation and oxidative stress increase autoantibodies in the elderly. Molecules 25: 3675. https://doi.org/10.3390/molecules25163675 ![]() |
[88] |
Barcenas-Morales G, Cortes-Acevedo P, Doffinger R (2019) Anticytokine autoantibodies leading to infection: early recognition, diagnosis and treatment options. Curr Opin Infect Dis 32: 330-336. https://doi.org/10.1097/QCO.0000000000000561 ![]() |
[89] |
Merkel PA, Lebo T, Knight V (2019) Functional analysis of anti-cytokine autoantibodies using flow cytometry. Front Immunol 10: 1517. https://doi.org/10.3389/fimmu.2019.01517 ![]() |
[90] |
Bastard P, Gervais A, Le Voyeret T, et al. (2021) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6: eabl4340. https://doi.org/10.1126/sciimmunol.abl4340 ![]() |
[91] |
Franceschi C, Salvioli S, Garagnani P, et al. (2017) Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Front Immunol 8: 982. https://doi.org/10.3389/fimmu.2017.00982 ![]() |
[92] | Fulop T, Larbi A, Pawelec G, et al. (2021) Immunology of aging: the birth of inflammaging. Clin Rev Allerg Immu 2021: 1-14. https://doi.org/10.1007/s12016-021-08899-6 |
[93] |
Cai D, Liu T (2012) Inflammatory cause of metabolic syndrome via brain stress and NF-κB. Aging 4: 98-115. https://doi.org/10.18632/aging.100431 ![]() |
[94] |
Reed RG (2019) Stress and immunological aging. Curr Opin Behav Sci 28: 38-43. https://doi.org/10.1016/j.cobeha.2019.01.012 ![]() |
[95] |
Klopack ET, Crimmins EM, Cole SW, et al. (2022) Social stressors associated with age-related T lymphocyte percentages in older US adults: Evidence from the US Health and Retirement Study. P Natl Acad Sci USA 119: e2202780119. https://doi.org/10.1073/pnas.2202780119 ![]() |
[96] |
Gouin JP, Hantsoo L, Kiecolt-Glaser JK (2008) Immune dysregulation and chronic stress among older adults: A review. Neuroimmunomodulat 15: 251-259. https://doi.org/10.1159/000156468 ![]() |
[97] |
Minciullo PL, Catalano A, Mandraffino G, et al. (2015) Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch Immunol Ther Ex 64: 111-126. https://doi.org/10.1007/s00005-015-0377-3 ![]() |
[98] |
Tajbakhsh A, Farahani N, Gheibihayat SM, et al. (2021) Autoantigen-specific immune tolerance in pathological and physiological cell death: Nanotechnology comes into view. Int Immunopharmacol 90: 107177. https://doi.org/10.1016/j.intimp.2020.107177 ![]() |
[99] |
Giefing-Kröll C, Berger P, Lepperdinger G, et al. (2015) How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 14: 309-321. https://doi.org/10.1111/acel.12326 ![]() |
[100] |
Kauffman CA, Yoshikawa TT (2001) Fungal infections in older adults. Clin Infect Dis 33: 550-555. https://doi.org/10.1086/322685 ![]() |
[101] |
Shea KM, Kammerer JS, Winston CA, et al. (2014) Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 179: 216-225. https://doi.org/10.1093/aje/kwt246 ![]() |
[102] |
Nikolich-Zugich J, Knox KS, Rios CT, et al. (2020) SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience 42: 505-514. https://doi.org/10.1007/s11357-020-00186-0 ![]() |
[103] |
Boraschi D, Italiani P (2014) Immunosenescence and vaccine failure in the elderly: Strategies for improving response. Immunol Lett 162: 346-353. https://doi.org/10.1016/j.imlet.2014.06.006 ![]() |
[104] |
Kogut I, Scholz JL, Cancro MP, et al. (2012) B cell maintenance and function in aging. Semin Immunol 24: 342-349. https://doi.org/10.1016/j.smim.2012.04.004 ![]() |
[105] |
Franceschi C, Capri M, Monti D, et al. (2007) Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128: 92-105. https://doi.org/10.1016/j.mad.2006.11.016 ![]() |
1. | Ulva Dewiyanti, Viska Noviantri, Reinert Y. Rumagit, Nonlinear system for cell population growth simulations in pulmonary tuberculosis infection, 2023, 216, 18770509, 462, 10.1016/j.procs.2022.12.158 | |
2. | Peng Feng, A spatial model to understand tuberculosis granuloma formation and its impact on disease progression, 2024, 0, 2752-2334, 10.1515/jncds-2023-0035 | |
3. | Ying He, Bo Bi, Conditions for extinction and ergodicity of a stochastic Mycobacterium tuberculosis model with Markov switching, 2024, 9, 2473-6988, 30686, 10.3934/math.20241482 | |
4. | Eduardo Ibargüen-Mondragón, M. Victoria Otero-Espinar, Miller Cerón Gómez, A within-host model on the interaction dynamics between innate immune cells and Mycobacterium tuberculosis, 2025, 22, 1551-0018, 511, 10.3934/mbe.2025019 |
Parameter | Description | Value | Reference |
growth rate of unfected Mtb | 600 -1000 day |
[19,23,30] | |
infection rate of Mtb | [13,30] | ||
elim. rate of infected Mtb by T cell | [13,30] | ||
nat. death rate of |
0028-0.0033 day |
[22,30] | |
nat. death rate of |
0.011 day |
[22,35,30] | |
growth rate of Mtb | 0.36 -0.52 day |
[12,20,38] | |
natural death rate of Mtb | 0.31 -0.52 day |
[39,30] | |
elim. rate of Mtb by |
[30] | ||
carrying cap. of Mtb in the gran. | [7] | ||
growth rate of T cells | [11] | ||
maximum recruitment of T cells | 5.000 day |
[11] | |
natural death rate of T cells | 0.33 day |
[35,30] | |
Average Mtb released by one |
0.05-0.2 day |
[30,35] |
Parameter | Description | Value | Reference |
growth rate of unfected Mtb | 600 -1000 day |
[19,23,30] | |
infection rate of Mtb | [13,30] | ||
elim. rate of infected Mtb by T cell | [13,30] | ||
nat. death rate of |
0028-0.0033 day |
[22,30] | |
nat. death rate of |
0.011 day |
[22,35,30] | |
growth rate of Mtb | 0.36 -0.52 day |
[12,20,38] | |
natural death rate of Mtb | 0.31 -0.52 day |
[39,30] | |
elim. rate of Mtb by |
[30] | ||
carrying cap. of Mtb in the gran. | [7] | ||
growth rate of T cells | [11] | ||
maximum recruitment of T cells | 5.000 day |
[11] | |
natural death rate of T cells | 0.33 day |
[35,30] | |
Average Mtb released by one |
0.05-0.2 day |
[30,35] |